Email: \u00a0Heesun.Huh@nbhn.net<\/a><\/li>\n<\/ul>\n\u00a0<\/p>\n
3. COPE for Pregnant Hispanic Women: Pilot Study Protocol<\/p>\n
\n- Lead Investigator: Anne Marie Gibeau<\/li>\n
- Email: Anne.Gibeau@nbhn.net<\/a>.net<\/li>\n
- Study Coordinator: Tayra Keshinover<\/li>\n
- Email: Tayra.Keshinover@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
4. An evaluation of the efficacy and safety of tapentadol oral solution in the treatment of post-operative acute pain requiring opioid treatment in pediatric subjects aged from birth to less than 18 years old.<\/p>\n
\n- Lead Investigator: Leonard Golden<\/a><\/li>\n
- Email: leonrad.golden@nbhn.net<\/a><\/li>\n
- Study Coordinator: Claudia Calderon<\/li>\n
- Email: \u00a0Claudia.Calderon@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
5. Lung Cancer Informational Study: A Decision Aid with HRQL Assessment to Reduce Costs in the Treatment of Non-small Cell Lung Cancer (NSCLC)<\/p>\n
\n- Lead Investigator: Richard Gralla<\/a><\/li>\n
- Email: richard.gralla@nbhn.net<\/a><\/li>\n
- Study Coordinator: Claudia Calderon<\/li>\n
- Email: \u00a0Claudia.Calderon@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
6. A phase II randomized, double-blind, placebo-controlled, multicenter study of VS-6063 in subjects with malignant pleural mesothelioma<\/p>\n
\n- Lead Investigator: Richard Gralla<\/a><\/li>\n
- Email: richard.gralla@nbhn.net<\/a><\/li>\n
- Study Coordinator: Claudia Calderon<\/li>\n
- Email: \u00a0Claudia.Calderon@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
7. Collection of Plasma Samples From Human Immunodeficiency Virus (HIV) Type 1 (HIV-1) Infected Individuals for the Clinical Evaluation of the Aptima HIV-1 Quant Dx Assay<\/p>\n
\n- Lead Investigator: Jason Leider<\/a><\/li>\n
- Email: jason.leider@nbhn.net<\/a><\/li>\n
- Study Coordinator: Shantum Misra<\/li>\n
- Email: \u00a0Shantum.Misra@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
8. HIV\/HCV testing<\/p>\n
\n- Lead Investigators: Jason Leider<\/a> and Yvette Calderon<\/a><\/li>\n
- Email: jason.leider@nbhn.net<\/a> and yvette.calderon@einstein.yu.edu<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
9. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA)<\/p>\n
\n- Lead Investigator: Jay Meisner<\/a><\/li>\n
- Email: jay.meisner@nbhn.net<\/a><\/li>\n
- Study Coordinator: Jeanne Russo<\/li>\n
- Email: \u00a0jeanne.russo@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
10. Intravenous ibuprofen for laparoscopic bariatric surgery<\/p>\n
\n- Lead Investigator: Mindaugas Pranevicius<\/a><\/li>\n
- Email: mindaugas.praneviciu@nbhn.net<\/a><\/li>\n
- Study Coordinator: Claudia Calderon<\/li>\n
- Email: \u00a0claudia.calderon@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
11. A multicenter, international, randomized, parallel group, double-blind, placebo-controlled Cardiovascular Safety & Renal Microvascular outcomE with LINAgliptin 5mg once daily in patients with type 2 diabetes mellitus at high vascular risk. (CARMELINA)<\/p>\n
\n- Lead Investigator: Ulrich Schubart<\/a><\/li>\n
- Email: ulrich.schubart@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Jeanne Russo<\/li>\n
- Email: \u00a0jeanne.jusso@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
12. A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus (EXSCEL)<\/p>\n
\n- Lead Investigator: Ulrich Schubart<\/a><\/li>\n
- Email: ulrich.schubart@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Jeanne Russo<\/li>\n
- Email: \u00a0jeanne.russo@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
13. GUIDing Evidence Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT)<\/p>\n
\n- Lead Investigator: Robert Siegel<\/a><\/li>\n
- Email: robert.siegel@nbhn.net<\/a><\/li>\n
- Study Coordinator: Cecilia Gutierrez<\/li>\n
- Email: \u00a0cecilia.gutierrez@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
14. A randomised, double-blind, parallel group, multicentre phase IIIb study to compare ticagrelor with clopidogrel treatment on the risk of cardiovascular death, myocardial infarction and ischaemic stroke in patients with established Peripheral Artery Disease (EUCLID \u2013 Examining Use of tiCagreLor In paD)<\/p>\n
\n- Lead Investigator: Seth I. Sokol<\/a>, MD<\/li>\n
- Email: seth.sokol@nbhn.net<\/a><\/li>\n
- Study Coordinator: Aline Baday<\/li>\n
- Email: \u00a0aline.baday@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
15. A Phase 3, Open-Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically-Suppressed, HIV-1 Positive Subjects<\/p>\n
\n- Lead Investigator: David K. Stein<\/a><\/li>\n
- Email: david.stein@nbhn.net<\/a><\/li>\n
- Study Coordinator: Angelo Seda<\/li>\n
- Email: \u00a0angelo.aeda@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
16. Medical Monitoring Project<\/p>\n
\n- Lead Investigator: David K. Stein<\/a><\/li>\n
- Email: david.stein@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
17. A Phase 3, Randomized, Open-Label, Switch Study to Evaluate F\/TAF in HIV-1 Positive Subjects who are Virologically Suppressed on Regimens containing FTC\/TDF<\/p>\n
\n- Lead Investigator: David K. Stein<\/a><\/li>\n
- Email: david.stein@nbhn.net<\/a><\/li>\n
- Study Coordinator: Angelo Seda<\/li>\n
- Email: \u00a0angelo.seda@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
18. Practice-Based Trial of Home BP Telemonitoring among Minority Stroke Survivors<\/p>\n
\n- Lead Investigator: Michelle A. Stern<\/a><\/li>\n
- Email: michelle.stern@nbhn.net<\/a><\/li>\n
- Study Coordinator: Aline Baday<\/li>\n
- Email: \u00a0aline.baday@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
19. IMPAACT 1077HS, HAART Standard Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere), Version 2.0<\/p>\n
\n- Lead Investigator: Andrew A. Wiznia<\/a><\/li>\n
- Email: andrew.wiznia@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Marlene Burey<\/li>\n
- Email: \u00a0marlene.burey@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
20. P1058A: Intensive pharmacokinetics studies of new classes of antiretroviral drug combinations in children, adolescents and young adults (Version 2.0)<\/p>\n
\n- Lead Investigator: Andrew A. Wiznia<\/a><\/li>\n
- Email: andrew.wiznia@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Marlene Burey<\/li>\n
- Email: \u00a0marlene.burey@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
21. A pilot study of psychiatric and antiretroviral medication concentrations in HIV-infected and uninfected children and adolescents: IMPAACT P1080: Version 1.0<\/p>\n
\n- Lead Investigator: Andrew A. Wiznia<\/a><\/li>\n
- Email: andrew.wiznia@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Marlene Burey<\/li>\n
- Email: \u00a0marlene.burey@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
22. IMPAACT P1093, Phase I\/II, Multi-Center, Open-Label Pharmacokinetic, Safety, Tolerability and Antiviral Activity of GSK1349572, a Novel Integrase Inhibitor, in Combination Regimens in HIV-1 Infected Infants, Children and Adolescents<\/p>\n
\n- Lead Investigator: Andrew A. Wiznia<\/a><\/li>\n
- Email: andrew.wiznia@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Marlene Burey<\/li>\n
- Email: \u00a0marlene.burey@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
23. Raltegravir pharmacokinetics and safety in neonates<\/p>\n
\n- Lead Investigator: Andrew A. Wiznia<\/a><\/li>\n
- Email: andrew.wiznia@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Marlene Burey<\/li>\n
- Email: \u00a0marlene.burey@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
24. A phase I trial to evaluate the safety and pharmacokinetics of raltegravir in HIV-1-exposed neonates at high risk of acquiring HIV-1 infection<\/p>\n
\n- Lead Investigator: Andrew A. Wiznia<\/a><\/li>\n
- Email: andrew.wiznia@einstein.yu.edu<\/a><\/li>\n
- Study Coordinator: Marlene Burey<\/li>\n
- Email: \u00a0marlene.burey@nbhn.net<\/a><\/li>\n<\/ul>\n
\u00a0<\/p>\n
\u00a0<\/p>\n<\/div>\n<\/div><\/div><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"
Clinical trials across many clinical disciplines are conducted at Jacobi Medical Center every year. Patients admitted to our center, and who meet specific criteria for studies, may be asked to participate in a research study. If you have questions about one of the specific studies listed, please contact the lead coordinator for that trial to learn more.Our hospital is currently actively recruiting patients for the following clinical studies:1. Genetic Studies of Chronic Kidney DiseaseLead Investigator: Anjali AcharyaEmail: anjali.acharya@nbhn.net\u00a02.\u00a0The Genetic Contribution … Continue reading “Clinical Trials”<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"parent":2,"menu_order":5,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/pages\/135"}],"collection":[{"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/comments?post=135"}],"version-history":[{"count":5,"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/pages\/135\/revisions"}],"predecessor-version":[{"id":3604,"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/pages\/135\/revisions\/3604"}],"up":[{"embeddable":true,"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/pages\/2"}],"wp:attachment":[{"href":"https:\/\/jacobimed.org\/wp-json\/wp\/v2\/media?parent=135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}